retatrutide triple agonist clinical trial Eli Lilly and Company's agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C retatrutide phase 2 trial obesity

US$ 24.61

★★★★★ 4.8 (9 reviews)

US$ 20.94

★★★★★ 4.1 (21 reviews)

US$ 25.25

★★★★★ 4.2 (14 reviews)

US$ 29.51

★★★★★ 4.6 (29 reviews)

US$ 26.73

★★★★★ 4.0 (10 reviews)

US$ 23.11

★★★★★ 4.3 (26 reviews)

US$ 29.00

★★★★★ 4.0 (6 reviews)

US$ 23.21

★★★★★ 4.3 (21 reviews)

US$ 29.50

★★★★★ 4.0 (26 reviews)

US$ 24.16

★★★★★ 4.7 (10 reviews)

US$ 23.18

★★★★★ 4.1 (16 reviews)

US$ 25.37

★★★★★ 4.3 (15 reviews)

US$ 25.82

★★★★★ 4.0 (25 reviews)

US$ 25.94

★★★★★ 4.2 (13 reviews)

US$ 22.37

★★★★★ 5.0 (10 reviews)

US$ 26.72

★★★★★ 4.1 (9 reviews)

US$ 22.66

★★★★★ 4.9 (21 reviews)

US$ 25.67

★★★★★ 4.7 (18 reviews)

US$ 26.49

★★★★★ 4.7 (14 reviews)

US$ 22.97

★★★★★ 4.6 (10 reviews)